Positive update on the development of new XF-platform drugs

摘要

Destiny Pharma has completed the initial phase of its project with MedPharm to develop new topical formulations of the company's novel XF-platform drugs.Further to forming the collaboration with MedPharm last year,the project has identified a range of new,stable XF formulations with promising drug release profiles and scope for the treatment of dermal and ocular infections.These formulations will form the basis of Destiny Pharma's preclinical and clinical programmes and treatments for both acute and chronic infections^ Selected formulations will also be incorporated into ongoing grant-funded projects,including the company's UK-China AMR,Innovate UK grant-funded collaboration.